Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | RORC | P51449 | 3/20 | 0.59 |
| ▸ | OSBP | P22059 | 2/20 | 0.59 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RORA | P35398 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | CDC25A | P30304 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL26653578 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL26653575 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL4276094 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL18407109 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL12430811 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL14420788 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL5341515 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL13429389 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL14898038 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNARORCOSBP | |
| 5Alpha-Cholestan-3Beta-Ol-6-One SCHEMBL7996326 | 0.98 | NPC1L1 (0.96) | NPC1L1USP2LMNARORCOSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 972 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062716-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | POPVAX PRIVATE LTD (IN) | 2026-03-05 | — | — | US | claimed |
| EP-4577196-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | Popvax Private Limited (IN) | 2025-07-02 | — | — | EP | claimed |
| WO-2025052180-A2 | LIPIDS AND LIPID NANOPARTICLES | Axelyf ehf. (IS) | 2025-03-13 | — | — | WO | claimed |
| WO-2024044178-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-02-29 | — | — | WO | claimed |
| EP-3368024-B1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES INC (US) | 2023-09-20 | — | — | EP | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-20220054429-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES, INC. | 2022-02-24 | — | — | US | claimed |
| EP-2411052-B1 | CARRIER COMPRISING A VITAMIN E DERIVATIVE AND ANNEXIN V | UCL BUSINESS LTD (GB) | 2020-10-07 | — | — | EP | claimed |
| US-20180311182-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES, INC. | 2018-11-01 | — | — | US | claimed |
| EP-3368024-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | Jay Pharma, Inc. (CA) | 2018-09-05 | — | — | EP | claimed |
| US-9566310-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2017-02-14 | — | — | US | claimed |
| US-20170027961-A1 | COMPOSITIONS FOR THE TREATMENT OF CATARACTS | Catacore, Inc. (US) | 2017-02-02 | — | — | US | claimed |
| US-9545392-B2 | Carrier comprising a vitamin E derivative | UCL BUSINESS PLC (GB) | 2017-01-17 | — | — | US | claimed |
| US-20160244761-A1 | LIPID PARTICLES WITH ASYMMETRIC CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2016-08-25 | — | — | US | claimed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | claimed |
| US-20140072536-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2014-03-13 | — | — | US | claimed |
| US-20120115771-A1 | CARRIER | UCL BUSINESS PLC (GB) | 2012-05-10 | — | — | US | claimed |
| EP-2411052-A2 | CARRIER COMPRISING A VITAMIN E DERIVATIVE | UCL Business PLC (GB) | 2012-02-01 | — | — | EP | claimed |
| WO-2010109212-A2 | CARRIER | UCL BUSINESS PLC (GB) | 2010-09-30 | — | — | WO | claimed |
| US-RE30538-E | VITAMIN D3 DERIVATIVE WHICH PROMOTES INTESTINAL CALCIUM TRANSPORT AND BONE CALCIUM MOBILIZATION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | NPC1L1 4043/4885USP2 3097/4885LMNA 484/4885 |
| US-20170027961-A1 | COMPOSITIONS FOR THE TREATMENT OF CATARACTS | CYP46A1, DHCR7, NR1H3 | NPC1L1 69/4885USP2 3111/4885LMNA 769/4885 |
| US-20140072536-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | NPC1L1 4043/4885USP2 3097/4885LMNA 484/4885 |
| US-20260062716-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | CETP, PLTP, LDLR | NPC1L1 5/4885USP2 3448/4885LMNA 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.